AR115883A1 - PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ADDICTION TO PSYCHOACTIVE SUBSTANCES AND / OR FOR THE PREVENTION OF RELIPS TO SUCH ADDICTION - Google Patents
PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ADDICTION TO PSYCHOACTIVE SUBSTANCES AND / OR FOR THE PREVENTION OF RELIPS TO SUCH ADDICTIONInfo
- Publication number
- AR115883A1 AR115883A1 ARP190102178A ARP190102178A AR115883A1 AR 115883 A1 AR115883 A1 AR 115883A1 AR P190102178 A ARP190102178 A AR P190102178A AR P190102178 A ARP190102178 A AR P190102178A AR 115883 A1 AR115883 A1 AR 115883A1
- Authority
- AR
- Argentina
- Prior art keywords
- addiction
- psychoactive substances
- treatment
- pharmaceutical composition
- prevention
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Addiction (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente se refiere a una composición farmacéutica para el tratamiento de la adicción crónica a sustancias psicoactivas y/o para prevenir la recaída a la adicción a sustancias psicoactivas, que comprende secretoma y/o exosomas derivados de células madre mesenquimales precondicionadas; y el uso de dicha composición para el tratamiento de la adicción a sustancias psicoactivas y prevención de la recaídas a dicha adicción. Reivindicación 1: Una composición farmacéutica para el tratamiento de la adicción a sustancias psicoactivas y/o para prevenir la recaída a la adicción a sustancias psicoactivas, caracterizada porque comprende entre 0,05 a 50 mg de proteínas totales de exosomas derivados de células madre mesenquimáticas precondicionadas durante su cultivo; y un excipiente farmacéuticamente aceptable. Reivindicación 6: La composición farmacéutica según la reivindicación 1, caracterizada porque las células madre mesenquimáticas se obtienen de tejido adiposo.The present refers to a pharmaceutical composition for the treatment of chronic addiction to psychoactive substances and / or to prevent relapse to addiction to psychoactive substances, comprising secretome and / or exosomes derived from preconditioned mesenchymal stem cells; and the use of said composition for the treatment of addiction to psychoactive substances and prevention of relapses to said addiction. Claim 1: A pharmaceutical composition for the treatment of addiction to psychoactive substances and / or to prevent relapse to addiction to psychoactive substances, characterized in that it comprises between 0.05 to 50 mg of total exosome proteins derived from preconditioned mesenchymal stem cells during its cultivation; and a pharmaceutically acceptable excipient. Claim 6: The pharmaceutical composition according to claim 1, characterized in that the mesenchymal stem cells are obtained from adipose tissue.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CL2018/050063 WO2020024071A1 (en) | 2018-08-03 | 2018-08-03 | Pharmaceutical composition for the treatment of addiction to psychoactive substances and/or the prevention of relapse to said addiction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR115883A1 true AR115883A1 (en) | 2021-03-10 |
Family
ID=63578894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190102178A AR115883A1 (en) | 2018-08-03 | 2019-08-01 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ADDICTION TO PSYCHOACTIVE SUBSTANCES AND / OR FOR THE PREVENTION OF RELIPS TO SUCH ADDICTION |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR115883A1 (en) |
| UY (1) | UY38319A (en) |
| WO (1) | WO2020024071A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022014605A (en) | 2020-05-19 | 2022-12-16 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use. |
| WO2024007670A1 (en) * | 2022-07-07 | 2024-01-11 | Pharward Biotechnology, Inc. Pte. Ltd. | Method for treating cocaine addiction |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170258843A1 (en) | 2016-03-14 | 2017-09-14 | AngioStem, Inc. | Stem cell mediated neuroregeneration and neuroprotection |
| AU2017354272A1 (en) | 2016-11-03 | 2019-05-23 | Exostem Biotec Ltd. | Mesenchymal stem cells populations, their products, and use thereof |
-
2018
- 2018-08-03 WO PCT/CL2018/050063 patent/WO2020024071A1/en active Application Filing
-
2019
- 2019-07-29 UY UY0001038319A patent/UY38319A/en not_active Application Discontinuation
- 2019-08-01 AR ARP190102178A patent/AR115883A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020024071A1 (en) | 2020-02-06 |
| UY38319A (en) | 2020-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR107871A1 (en) | COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF SOLID TUMORS | |
| UY37565A (en) | IARN ALFA-1 ANTITRIPSIN AGENTS (AAT), COMPOSITIONS INCLUDING IARN AAT AGENTS AND METHODS OF USE | |
| CO6331425A2 (en) | COMPOSITIONS THAT INCLUDE N- (3,4-DIFLUORO-2- (2-FLUORO-4-IODOFENILAMINO) 6-METOXIFENIL) -1- (2,3-DIHYDROXIPROXIPROPIL) CICLOPROPAN-1-SULFAMIDA | |
| BR112016000561B8 (en) | Therapeutically active compounds, use thereof, pharmaceutical composition and use thereof | |
| CL2019001366A1 (en) | Buffered formulations exendin (9-39). | |
| AR090349A1 (en) | COMBINATION THERAPY FOR PROLIFERATIVE DISORDERS, KIT AND USE | |
| AR108889A1 (en) | COMBINATIONS FOR CANCER TREATMENT | |
| AR113422A2 (en) | RECONSTITUTED SURFACTIVE AGENTS HAVING IMPROVED PROPERTIES | |
| AR112103A1 (en) | COMPOUNDS FOR THE TREATMENT OF TNBC | |
| DOP2016000254A (en) | PHARMECEUTIC FORMULATIONS OF PAN-RAF QUINASE INHIBITOR, PROCEDURES FOR THEIR PREPARATION, AND METHODS OF USE. | |
| CO2017012766A2 (en) | Orodispersible dosing unit containing an estetrol component | |
| PA8809601A1 (en) | ANTI-RETROVIRAL COMBINATION | |
| CO2019009000A2 (en) | Pharmaceutical combinations to treat cancer | |
| AR115883A1 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ADDICTION TO PSYCHOACTIVE SUBSTANCES AND / OR FOR THE PREVENTION OF RELIPS TO SUCH ADDICTION | |
| ECSP21031200A (en) | USE OF REBOXETIN FOR THE TREATMENT OF NARCOLEPSY | |
| CL2023003327A1 (en) | Inhibitors of the menin-mll interaction | |
| BR112018014723A2 (en) | bacterial ghosts for cancer treatment | |
| UY31826A (en) | PEPTIDE COMPOUND AND ITS USE | |
| BR112015012497A2 (en) | pharmaceutical combinations | |
| AR102661A1 (en) | TOPIC USE DRUG FOR SKIN INJURIES AND MUCOSES ASSOCIATED WITH BULLY EPIDERMOLISIS | |
| DOP2021000028A (en) | DENDRIMERAL FORMULATIONS | |
| AR103636A1 (en) | METHODS OF TREATMENT OF POSTERPEPTIC NEURALGY WITH A TOPICAL FORMULATION OF AN ESPIRO-OXINDOL COMPOUND | |
| AR108792A1 (en) | COMPOSITIONS THAT INCLUDE TIMOLOL | |
| CU20160194A7 (en) | VACCINE COMPOSITION THAT INCLUDES ONE MUTANT OF HUMAN INTERLEUCINE-15 | |
| AR101227A1 (en) | COMBINATIONS OF A N-TIAZOLIL-4-PHENOXIBENCENOSULFONAMIDE DERIVATIVE AND A PHARMACEUTICALLY ACTIVE AGENT SELECTED FROM GABAPENTINE AND PREGABALINE TO TREAT PAIN |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |